Slater Technology Fund-backed company to be acquired by Novartis

PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday.

The company was formed through a merger with the Slater Technology Fund-backed company Mnemosyne Pharmaceuticals. Mnemosyne developed a drug-discovery program targeting the creation of novel therapeutics to treat cognitive dysfunction and a broad range of central nervous system disorders.

Slater, an evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island, invested $1.5 million in Mnemosyne, which became an ownership stake in Cadent. Slater noted that former Mnemosyne co-founder Frank Menniti has gone on to start MindImmunue Therapeutics, another Slater-backed company.

Mnemosyne moved to Cambridge in 2015 as Luc Therapeutics after finishing an $11.5 million Series A financing round, and merged with Ataxion in 2017 to become Cadent.

“It is incredibly gratifying to see seed investments blossom in so many ways. Congratulations to [CEO of Cadent Therapeutics] Jodie Morrison and her team on creating such a great outcome for all, and to the Mnemosyne founders, who teamed with Richard Horan and Slater a decade ago,” said Thorne Sparkman, managing director of Slater. “This kind of success quite literally fuels the impact that entrepreneurs like the Mnemosyne founders can make by augmenting Slater’s evergreen investment in the next generation of ventures. We cannot wait to pay it forward.”

Slater said the deal marked the fourth positive liquidity event for the fund in the past two years.

Purchase Now

Latest News

RI Bio COVID-19 – What’s Next?

Governor Raimondo Shows The Path Forward Governor Gina Raimondo has announced her plan for reopening the RI economy.  With the stay-at-home order set to expire on May 8th, the phased approach will begin on May 9th. Governor Raimondo said Phase 1 of her reopening plan...

Ocean Biomedical Announces Groundbreaking Malaria Vaccine Discovery

Screening Platform Can Help Develop Novel Vaccine Candidates Against Future Coronaviruses and Human Schistosomiasis NEWS PROVIDED BY Ocean Biomedical Apr 22, 2020, 11:05 ET PROVIDENCE, R.I., April 22, 2020 /PRNewswire/ -- Ocean Biomedical is pleased to announce a...

Development agreement outlined for 101 College St. project

Development agreement outlined for 101 College St. project

By Michael C. Bingham The city has reached a tentative development agreement that would pave the way for a transformative $100 million life-sciences incubator in the heart of downtown New Haven. Developer Winstanley Enterprises LLC of Concord, Mass. has proposed to...

Biotech Industry News